Search Results - "Wallstroem, Erik"

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study by Havrdová, Eva, Belova, Anna, Goloborodko, Alla, Tisserant, Anne, Wright, Andrew, Wallstroem, Erik, Garren, Hideki, Maguire, Ralph Paul, Johns, Donald R.

“…The objective of this study was to assess the effect of secukinumab, a monoclonal antibody that inhibits interleukin (IL)-17A, on number of new active brain…”
Get full text

An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy by Querol, Luis, Lewis, Richard A., Hartung, Hans‐Peter, Van Doorn, Pieter A., Wallstroem, Erik, Luo, Xiaodong, Alonso‐Alonso, Miguel, Atassi, Nazem, Hughes, Richard A. C.

“…Background and Aims Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune‐mediated disease of the peripheral nerves, with significant unmet…”
Get full text

Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial by Mercier, Francois, Bornkamp, Bjoern, Ohlssen, David, Wallstroem, Erik

“…Understanding the dose–response relationship is a key objective in Phase II clinical development. Yet, designing a dose‐ranging trial is a challenging task, as…”
Get full text

Effect of RIPK1 Inhibitor, SAR443820, on Serum Neurofilament Light Levels in Patients with Multiple Sclerosis: A Phase 2 Trial Design (P6-3.011) by Montalban, Xavier, Kuhle, Jens, Fox, Robert, Vartanian, Timothy, Horakova, Dana, Filippi, Massimo, Roos, Ernest, Wallstroem, Erik, Atassi, Nazem

“…Abstract only…”
Get full text

Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008) by Querol, Luis, Lewis, Richard, Hartung, Hans-Peter, Van Doorn, Pieter, Wallstroem, Erik, Luo, Xiaodong, Alonso, Miguel Alonso, Atassi, Nazem, Hughes, Richard

“…Abstract only…”
Get full text

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007) by Giovannoni, Gavin, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Djukic, Biljana, Truffinet, Philippe, Wallstroem, Erik, Vermersch, Patrick

“…Abstract only…”
Get full text

Inhibition of CD40L with Frexalimab in Multiple Sclerosis by Vermersch, Patrick, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Truffinet, Philippe, Djukic, Biljana, Wallstroem, Erik, Giovannoni, Gavin

“…In a phase 2 trial involving participants with multiple sclerosis, the CD40L inhibitor frexalimab reduced the accumulation of new lesions on MRI at week 12 of…”
Get full text

Relationship between MRI Lesion Count and B Cell Count Reduction under Ofatumumab Treatment (P5.348) by Savelieva, Marina, Kahn, Joseph, Wallstroem, Erik, Leppert, David

“…Abstract only…”
Get full text

Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study (2260) by Syed, Sana, Yonkers, Nicole, LaGanke, Christopher, Honeycutt, William David, Traboulsee, Anthony, Wynn, Daniel, Wray, Sibyl, Wallstroem, Erik, Dukovic, Deborah, Turner, Timothy

“…Abstract only…”
Get full text

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study by Selmaj, Krzysztof, Prof, Li, David KB, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Stüve, Olaf, MD, Rieckmann, Peter, Prof, Montalban, Xavier, Prof, Ziemssen, Tjalf, MD, Auberson, Lixin Zhang, MD, Pohlmann, Harald, MSc, Mercier, Francois, PhD, Dahlke, Frank, MD, Wallström, Erik, MD

“…Summary Background Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to…”
Get full text

Variation in interleukin 7 receptor [alpha] chain (IL7R) influences risk of multiple sclerosis by Lundmark, Frida, Duvefelt, Kristina, Iacobaeus, Ellen, Kockum, Ingrid, Wallström, Erik, Khademi, Mohsen, Oturai, Annette, Ryder, Lars P, Saarela, Janna, Harbo, Hanne F, Celius, Elisabeth G, Salter, Hugh, Olsson, Tomas, Hillert, Jan

“…Multiple sclerosis is a chronic, often disabling, disease of the central nervous system affecting more than 1 in 1,000 people in most western countries. The…”
Get full text

Evolution of clinical trials in multiple sclerosis by Zhang, Yinan, Salter, Amber, Wallström, Erik, Cutter, Gary, Stüve, Olaf

“…Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This…”
Get full text

Low-dose Subcutaneous Anti-CD20 Therapy Effectively Depletes B Cells and Ameliorates Central Nervous System Autoimmunity (P2.359) by Smith, Paul, Huck, Catherine, Wegert, Vanessa, Schmid, Cindy, Dunn, Robert, Leppert, David, Wallstroem, Erik

“…Abstract only…”
Get full text

Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion (S24.003) by Smith, Paul, Huck, Catherine, Schmid, Cindy, Baumgartner, Reto, Stuber, Nathalie, Theil, Diethilde, Cordoba, Francisco, Wallstroem, Erik, Leppert, David

“…Abstract only…”
Get full text

Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis by Kornek, Barbara, Storch, Maria K., Weissert, Robert, Wallstroem, Erik, Stefferl, Andreas, Olsson, Tomas, Linington, Christopher, Schmidbauer, Manfred, Lassmann, Hans

“…Recent magnetic resonance (MR) studies of multiple sclerosis lesions indicate that axonal injury is a major correlate of permanent clinical deficit. In the…”
Get full text

Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis : A Comparative Quantitative Study of Axonal Injury in Active, Inactive, and Remyelinated Lesions by Kornek, Barbara, Storch, Maria K, Weissert, Robert, Wallstroem, Erik, Stefferl, Andreas, Olsson, Tomas, Linington, Christopher, Schmidbauer, Manfred, Lassmann, Hans

“…Recent magnetic resonance (MR) studies of multiple sclerosis lesions indicate that axonal injury is a major correlate of permanent clinical deficit. In the…”
Get full text

Neurostatus e-Scoring Increases Quality of the Expanded Disability Status Scale (EDSS) Assessments: First Experience in a Phase 3 Clinical Trial with Siponimod in Secondary Progressive Multiple Sclerosis (P2.112) by DSouza, Marcus, John, Roland, Rust, Heiko, Micicunaite, Kristina, Andelova, Michaela, Lorscheider, Johannes, Gysin, Shauna, Hunter, Brian, Wallstroem, Erik, Schnyder, Franz, Kappos, Ludwig

“…Abstract only…”
Get full text

Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084) by Kappos, Ludwig, Bar-Or, Amit, Cree, Bruce, Fox, Robert, Giovannoni, Gavin, Gold, Ralf, Vermersch, Patrick, Bhasin, Priya, Arnould, Sophie, Sidorenko, Tatiana, Wallstroem, Erik

“…Abstract only…”
Get full text

T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis by Khademi, Mohsen, Illes, Zsolt, Gielen, Alexander W, Marta, Monica, Takazawa, Naruhiko, Baecher-Allan, Claire, Brundin, Lou, Hannerz, Jan, Martin, Claes, Harris, Robert A, Hafler, David A, Kuchroo, Vijay K, Olsson, Tomas, Piehl, Fredrik, Wallstrom, Erik

“…T cell Ig- and mucin-domain-containing molecules (TIMs) comprise a recently described family of molecules expressed on T cells. TIM-3 has been shown to be…”
Get full text

Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? by Brynedal, Boel, Khademi, Mohsen, Wallström, Erik, Hillert, Jan, Olsson, Tomas, Duvefelt, Kristina

“…Abstract The aetiology of multiple sclerosis (MS), an autoimmune demyelinating disease of the central nervous system (CNS), includes both genetic and…”
Get full text